腱鞘巨细胞瘤的经济和人文负担:靶向文献综述
靶向文献综述数据集,分析腱鞘巨细胞瘤的流行病学、治疗模式及经济人文负担。

基本信息
资源简介
腱鞘巨细胞瘤的经济和人文负担:靶向文献综述
【一句话概览】
本数据集是 figshare 公开的文本数据集,收录 5 个文件、合计 173.36 KB,主题涵盖 TGCT、PVNS、patient-reported outcomes、quality of life、treatment patterns,可用于医学自然语言处理(实体识别、信息抽取等),CC BY 4.0 许可开放获取。
【数据集背景】
本数据集源站标题为《The economic and humanistic burden of tenosynovial giant cell tumor: a targeted literature review》。配套论文《The economic and humanistic burden of tenosynovial giant cell tumor: a targeted literature review》发表于 Future Oncology(2025),DOI:10.1080/14796694.2025.2520744。项目资助方:This research and medical writing support were funded by Deciphera Pharmaceuticals, LLC, Waltham, MA, USA.。源站首次发布:2025-06-23。
【数据内容】
源站原始描述:To understand the epidemiology, treatment patterns, economic burden, and humanistic burden of tenosynovial giant cell tumor (TGCT) in the contemporary treatment landscape. Embase, MEDLINE, and select conferences were searched to identify studies published between 1 January 2013, and 22/23 August 2023 (database dependent) that included ≥ 20 TGCT patients (≥ 40 for humanistic burden studies). For economic outcomes and treatment patterns, data from 1 January 2008, and later were included. A total o…
【数据结构与技术规格】
文件数 5 个,合计 173.36 KB。Burden of Illness in TGCT Supplementary Material_16May2025.docx:application/vnd.openxmlformats-officedocument.wordprocessingml.document,27.50 KB。Burden of Illness in TGCT Supplementary Table 1_16May2025.docx:application/vnd.openxmlformats-officedocument.wordprocessingml.document,36.27 KB。Burden of Illness in TGCT Supplementary Table 2_16May2025.docx:application/vnd.openxmlformats-officedocument.wordprocessingml.document,36.44 KB。数据集 DOI:10.6084/m9.figshare.29380424.v1。
【主题与分类】
源站学科分类:Medicine、Genetics、Physiology、Pharmacology、Biological Sciences not elsewhere classified、Cancer。主题标签:TGCT、PVNS、patient-reported outcomes、quality of life、treatment patterns、cost、orthopedic surgery、CSF1R。
【适用方向】
文本类数据可用于医学自然语言处理,如命名实体识别、信息抽取与文本分类。
【获取与许可】
源站页面:https://tandf.figshare.com/articles/dataset/The_economic_and_humanistic_burden_of_tenosynovial_giant_cell_tumor_a_targeted_literature_review/29380424
使用许可:CC BY 4.0(https://creativecommons.org/licenses/by/4.0/)。
规范引用:The economic and humanistic burden of tenosynovial giant cell tumor: a targeted literature review. Taylor & Francis. van de Sande, Michiel; Blay, Jean-Yves; Tap, William; Lee, Max; Kaiser, Emily; Beaver, Steph; et al
【使用注意】
· 源站最后修改于 2025-08-05,引用时请注意版本时效。
下载信息
注册下载
需要注册 Kaggle 账号并登录后下载,适合需要跟踪下载记录和使用 API 的用户。
暂未开放公开下载
无需注册即可直接获取公开样本或文档,适合快速预览和评估数据集质量。
免登录当前数据集主要来源为 Kaggle 公开托管,完整影像包建议通过原始链接或 Kaggle API 获取。
使用方式
数据集获取(Figshare)
- 源站标题:The economic and humanistic burden of tenosynovial giant cell tumor: a targeted literature review
- DOI:10.6084/m9.figshare.29380424.v1
- 发布日期:2025-06-23
- 文件数:5 个
- 文件总体积:173.36 KB
- 源站页面:https://tandf.figshare.com/articles/dataset/The_economic_and_humanistic_burden_of_tenosynovial_giant_cell_tumor_a_targeted_literature_review/29380424
命令行下载
curl -L -o "Burden of Illness in TGCT Supplementary Material_16May2025.docx" "https://ndownloader.figshare.com/files/55557947"
curl -L -o "Burden of Illness in TGCT Supplementary Table 1_16May2025.docx" "https://ndownloader.figshare.com/files/55557950"
curl -L -o "Burden of Illness in TGCT Supplementary Table 2_16May2025.docx" "https://ndownloader.figshare.com/files/55557953"
curl -L -o "Burden of Illness in TGCT Supplementary Table 3_16May2025.docx" "https://ndownloader.figshare.com/files/55557956"
curl -L -o "Burden of Illness in TGCT Supplementary Table 4_16May2025.docx" "https://ndownloader.figshare.com/files/55557959"
文件清单
Burden of Illness in TGCT Supplementary Material_16May2025.docx(27.50 KB)Burden of Illness in TGCT Supplementary Table 1_16May2025.docx(36.27 KB)Burden of Illness in TGCT Supplementary Table 2_16May2025.docx(36.44 KB)Burden of Illness in TGCT Supplementary Table 3_16May2025.docx(25.35 KB)Burden of Illness in TGCT Supplementary Table 4_16May2025.docx(47.79 KB)
文件总体积 173.36 KB(源站 API 实测)。
数据说明
To understand the epidemiology, treatment patterns, economic burden, and humanistic burden of tenosynovial giant cell tumor (TGCT) in the contemporary treatment landscape.
Embase, MEDLINE, and select conferences were searched to identify studies published between 1 January 2013, and 22/23 August 2023 (database dependent) that included ≥ 20 TGCT patients (≥ 40 for humanistic burden studies). For economic outcomes and treatment patterns, data from 1 January 2008, and later were included.
A total of 35 studies were included. The incidence of TGCT was TGCT has a high burden, which can be exacerbated by repeat surgeries. Systemic therapies may improve disease and quality of life outcomes in some patients with tumors that are locally advanced or in complicated anatomical locations.
Tenosynovial giant cell tumor (TGCT) is a rare disease that affects the joints and surrounding tissues. We reviewed published studies to understand how common TGCT is, current treatments, healthcare-related services and costs, and its impact on patients. Studies confirmed that TGCT is rare and that it impacts a relatively young population. Patients with TGCT commonly experience pain and stiffness and have less mobility and worse overall quality of life compared with the general population. Most patients with symptoms are treated with surgery. However, TGCT can come back after surgery in up to 2 out of 3 patients, potentially requiring them to undergo additional surgeries, which may be expensive and worsen symptoms. Alternatively, medications can be used for treatment and improve symptoms and quality of life for many patients. However, medications are not currently widely available and some are associated with negative side effects. More studies on existing medications and new medications that have fewer side effects are needed. In addition to surgery and medications, many patients receive physical therapy. Treatment decisions should consider the risks and benefits of all options on an individual basis.
许可
CC BY 4.0
引用
学术使用请引用 DOI 10.6084/m9.figshare.29380424.v1(source: https://tandf.figshare.com/articles/dataset/The_economic_and_humanistic_burden_of_tenosynovial_giant_cell_tumor_a_targeted_literature_review/29380424)。
需要用于商业化训练或医疗器械注册(NMPA/FDA)?
公开数据往往缺乏完整的病理回证与专家标注。千方医数集依托陕川双基地与超十家三甲医院直连,提供完全合规、去标识化、支持注册级质控的专病数据集交易服务。




